CME credits: 1.00

Valid until: 20-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/quality-indicators-how-do-you-compare-part-2/17862/



  
    In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.

Quality Indicators: How Do You Compare? Part 2

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Managing Immune-Related Adverse Events With Immunotherapies

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Overcoming Barriers to Equitable Care in HNSCC

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Quality Indicators: How Do You Compare? Part 2

Download our free app to listen on your phone